Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Oral rigosertib: Preliminary Phase II data

Preliminary data from the open-label, U.S. Phase II ONTARGET trial in 29 patients with transfusion-dependent, low or intermediate-1 MDS showed that twice-daily 560 mg oral rigosertib for

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE